Irinotecan's molecular mechanisms against cancer: a primary system biology and chemoinformatics approach for novel formulation development
DOI:
https://doi.org/10.12923/cipms-2025-0005Keywords:
cancer, molecular processes, chemoinformatics approachAbstract
Cancer is the third most common type of cancer generally. It affects 6.1% of the entire world’s population and kills 9.2% of all people of both sexes. Even though people with colon cancer have a number of chemotherapies and surgeries to choose from, the disease often returns after the first treatment.
AutoDockVina by PyRx 0.8v was used to do molecular docking. The admetSAR2.0 web server was employed for ADMET analysis. The MolSoft and ADVERPred tools were applied to predict the drug's potential for abuse and its potential for side effects.
The anti-tumor effects of irinotecan may be aimed at the metabolic processes and Ras and PI3K-Akt signaling pathways that help cancer grow.
Gene set enrichment and network analysis proved useful in determining possible protein targets of Irinotecan. Molecular docking revealed how Irinotecan and Vitamin E TPGS interact with EGFR. Moreover, we found that vitamin E TPGS possesses the potential to be an efficient inhibitor for the efflux pump substrate medications such as irinotecan. In addition, the network we created was able to demonstrate how pathways contribute to the protein molecules of irinotecan being able to target cancers. Lastly, we conclude that irinotecan's effectiveness in combating colon cancer is due to the formation of a network of protein-pathway links.
References
1. Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148:104398.
2. Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001;19(5):1501-18.
3. Cunningham D, Maroun J, Vanhoefer U, Van Cutsem E. Optimizing the use of irinotecan in colorectal cancer. Oncologist. 2001;6(S4):17-23.
4. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996;14(3):709-15.
5. Ahire ED, Kshirsagar SJ. Efflux pump inhibitors: New hope in microbial multidrug resistance. Role of Efflux Pump Inhibitors in multidrug resistance protein (P-gp). CAI. 2022;10(9):1-7.
6. Linn SC, Pinedo HM, van Ark‐Otte J, Van Der Valk P, Hoekman K, Honkoop AH, Vermorken JB, et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer. 1997;71(5):787-95.
7. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996;14(3):709-15.
8. Fujita KI, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol. 2015;21(43):12234.
9. Wei J, Sun Z, Shi L, Hu S, Liu D, Wei H. Molecular mechanism of chrysin in hepatocellular carcinoma treatment based on network pharmacology and in vitro experiments. NPC. 2021;16(12):1934578X211067294.
10. Singh P, Singh RS, Kushwaha PP, Kumar S. Anticancer and neuroprotective activity of Chrysin: Recent advancement. In Phytochemistry: An in-silico and in-vitro. Singapore: Springer; 2019:183-202.
11. Lee HS, Lee IH, Kang K, Park SI, Moon SJ, Lee CH, et al. A network pharmacology study on the molecular mechanisms of FDY003 for breast cancer treatment. Evid Based Complement Alternat Med. 2021;2021:3919143.
12. Lee HS, Lee IH, Kang K, Park SI, Jung M, Yang SG, et al. Network pharmacology-based dissection of the comprehensive molecular mechanisms of the herbal prescription FDY003 against estrogen receptor-positive breast cancer. Nat Prod Comm. 2021;16(9): 1934578X211044377.
13. Lee HS, Lee IH, Kang K, Park SI, Jung M, Yang SG, et al. A network pharmacology perspective investigation of the pharmacological mechanisms of the herbal drug FDY003 in gastric cancer. Nat Prod Comm. 2022;17(1):1934578X211073030.
14. Xiao K, Li K, Long S, Kong C, Zhu S. Potential molecular mechanisms of Chaihu-Shugan-San in treatment of breast cancer based on network pharmacology. Evid Based Complement Alternat Med. 2020;2020:3670309.
15. Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 2006;32(7):491-503.
16. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol. 2009;11(1):80-91.
17. Kui L, Kong Q, Yang X, Pan Y, Xu Z, Wang S, Chen J, Wei K, Zhou X, Yang X, Wu T. High-throughput in vitro gene expression profile to screen of natural herbals for breast cancer treatment. Front Oncol. 2021;11:684351.
18. Wu J, Luo D, Li S. Network pharmacology-oriented identification of key proteins and signaling pathways targeted by Xihuang pill in the treatment of breast cancer. Breast Cancer. 2020:12;267-77.
19. Huang S, Chen Y, Pan L, Fei C, Wang N, Chu F, et al. Exploration of the potential mechanism of Tao Hong Si Wu decoction for the treatment of breast cancer based on network pharmacology and in vitro experimental verification. Front Oncol. 2021;11:731522.
20. Zhang YZ, Yang JY, Wu RX, Fang C, Lu H, Li HC, et al. Network pharmacology – based identification of key mechanisms of xihuang pill in the treatment of triple-negative breast cancer stem cells. Front Pharmacol. 2021;12:714628.
21. Schenone M, Dančík V, Wagner BK, Clemons PA. Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol. 2013;9(4):232-40.
22. Glaab E, Baudot A, Krasnogor N, Schneider R, Valencia A. Enrich Net: network-based gene set enrichment analysis. Bioinformatics. 2012;28(18):451-7.
23. Scotti L, JB Mendonca Junior F, M Ishiki H, F Ribeiro F, K Singla R, M Barbosa Filho J, S DaSilva M, T Scotti M. Docking studies for multi-target drugs. Current Drug Targets. 2017;18(5):592-604.
24. Leadbeater NE, Marco M. Preparation of polymer-supported ligands and metal complexes for use in catalysis. Chem Rev. 2002;102(10):3217-74.
25. Mukherjee S, Balius TE, Rizzo RC. Docking validation resources: protein family and ligand flexibility experiments. J Chem Inf Model. 2010;50(11):1986-2000.
26. Morris, G.M., Lim-Wilby, M. Molecular Docking. In: A. Kukol (eds). Molecular modeling of proteins. Methods Molecular Biology™. Humana Press; 2008.
27. Leimkuhler B, Matthews C. Molecular dynamics. Interdiscipl Appl Math. 2015;39:443.
28. Surana KR, Ahire ED, Sonawane VN, Talele SG, Talele GS. Molecular Modeling: Novel techniques in food and nutrition development. In: Natural food products and waste recovery. Apple Academic Press; 2021:17-31.
29. Yang K, Zeng L, Ge J. Exploring the pharmacological mechanism of Danzhi Xiaoyao powder on ER-positive breast cancer by a network pharmacology approach. Evid Based Complement Alter Med. 2018;2018.
30. Surana KR, Ahire ED, Sonawane VN, Talele SG. Biomolecular and molecular docking: A modern tool in drug discovery and virtual screening of natural products. In: Applied Pharmaceutical Practice and Nutraceuticals. Apple Academic Press; 2021:209-23.
31. Irshad R, Raj N, Gabr GA, Manzoor N, Husain M. Integrated network pharmacology and experimental analysis unveil multi-targeted effect of 18α-glycyrrhetinic acid against non-small cell lung cancer. Front Pharmacol. 2022;13:1018974.
32. Ahire ED, Sonawane VN, Surana KR, Talele GS. Drug discovery, drug-likeness screening, and bioavailability: Development of drug-likeness rule for natural products. In: Applied pharmaceutical practice and nutraceuticals. Apple Academic Press; 2021:191-208.
33. Luta I, Maria G. In-silico modulation of the irinotecan release from a functionalized MCM-41 support. Chem Biochem Engin Quart. 2012;26(4):309-20.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
